Within  weeks prior to randomization: Aspartate aminotransferase (AST) must be =< . x ULN for the lab\r\n* Note: If alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =< . x ULN; if both were performed, the AST must be =< . x ULN
Within  days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<  x ULN (AST and/or ALT =<  x ULN for patients with liver involvement)
Obtained within  days prior randomization: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =<  x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =<  x ULN
Aspartate aminotransferase (AST) ? . x ULN; alanine aminotransferase (ALT) ? . x ULN; AST/ALT <  x ULN if liver involvement
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBILI) each < ULN; however, ALT, AST, and TBILI each ? ULN is acceptable if the elevation is considered due to PTLD involvement of the liver.
Alanine aminotransaminase (ALT) and aspartate aminotransferase (AST) =< . x ULN, unless clearly due to disease involvement
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN in patients with liver metastasis) (=<  days prior to registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =<  x ULN) must be met within  days of CD
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <  x the institutional ULN\r\n* Note that physician attestation of patient having no known history of liver disease can take the place of bilirubin and AST/ALT labs
In case alkaline phosphatase is >. x ULN patients are eligible for inclusion if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? . x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN; for patients with hepatic metastases, ALT and AST =<  x ULN
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < . x ULN; if liver metastases, ALT/AST =< . x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< . x ULN (or =<  x ULN for subjects with liver metastasis)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST), should be less than or equal to . x ULN (CTCAE v., grade ); for patients with liver metastases, ALT/AST should be less than or equal to . x ULN (CTCAE v. grade )
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? . x ULN; AST and ALT ?   ULN for patients with liver metastasis
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN; if the patient has liver metastases, ALT and AST must be =<  x ULN.
Aspartate and alanine aminotransferase (AST and ALT) =< . x ULN; =< . x ULN if there is liver involvement secondary to tumor
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < . x ULN or <  x the ULN if liver metastasis performed within  days prior to the date of registration
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at =< . x ULN (in case of liver metastasis AST/ALT at =< . x ULN)
Alanine aminotransferase (ALT) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > x ULN for patients without tumor involvement of the liver or > x ULN for patients with tumor involvement of the liver.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?. x the upper limit of normal (ULN), if no liver involvement or ? x ULN with liver involvement
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =<  x the ULN for the reference lab (=<  x the ULN if there is evidence of hepatic involvement by malignant disease)
Aspartate aminotransferase (AST) and alanine-aminotransferase (ALT) levels =< . x ULN or, for patients with documented metastatic disease to the liver, AST and ALT levels =<  x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN with the following exception: patients with liver involvement: AST and/or ALT =<  x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN (unless due to liver involvement)
Alanine aminotransferase (ALT) =< . x ULN unless demonstrated lymphoma involvement of the liver, performed within  days prior to day  of protocol therapy
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? . times the ULN range of each institution. With the following exceptions: subjects with documented liver metastases; AST and ALT <  x ULN.
STRATUM B: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =<  x ULN; for the purposes of eligibility the ULN of ALT and AST is  U/L
STRATUM C: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =<  x ULN; for the purposes of eligibility, the ULN of ALT and AST is  U/L
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? . institutional ULN or, in the case of liver involvement by the primary disease AST/ALT ?  x ULN
STUDY TREATMENT: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< .  ULN within  days prior to the first study treatment with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =<   ULN.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? x the institutional ULN, except for people with liver involvement by their lymphoma, who may be included if AST/ALT ? x the institutional ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<  x ULN without liver metastasis; =<  x ULN with liver metastasis
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . times the ULN (=<  x ULN for patients with liver involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN except for subjects with liver mets for whom ALT and AST should be =<  x ULN
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < x ULN unless considered due to leukemic involvement
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >  x ULN (or >  x ULN for patients with concurrent liver metastasis)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN with the exception that patients with liver involvement: AST and/or ALT =<  x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ? .  ULN or AST and ALT levels ?  x ULN for subjects with documented metastatic disease to the liver; patient with history of unconjugated hyperbilirubinemia with otherwise acceptable liver enzyme levels (as per above criteria) may have higher bilirubin levels
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x institutional ULN or, in the case of liver involvement by the primary disease AST/ALT =<  x ULN
Obtained within  days prior to the first study treatment (cycle , day ): aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN with the following exception: ) patients with documented liver metastases: AST and/or ALT =<  x ULN
Within  days of the first study treatment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< . x ULN or AST and ALT levels =<  x ULN (for subjects with documented metastatic disease to the liver)
Within  days prior to cycle  day  of treatment: Aspartate aminotransferase (AST) =< . x ULN (. x ULN if liver involvement)
Within  days prior to cycle  day  of treatment: Alanine aminotransferase (ALT) =< . x ULN (. x ULN if liver involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN, unless clearly due to disease involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x institutional ULN (=<  x institutional ULN if there is liver metastasis)
Aspartate aminotransferase (AST), level =< . x ULN, and an alanine aminotransferase (ALT) level =< . x ULN or, for subjects with documented metastatic disease to the liver, AST and ALT levels =<  x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Within  days prior to the first study treatment (cycle , day ): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =<  x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =<  x ULN
FULL STUDY INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for patients with liver involvement of their cancer)
Aspartate aminotransferase or alanine aminotransferase =< . x ULN (=< . x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) =< . x ULN, aspartate aminotransferase (AST) =< . x ULN); ALT and AST =<  x ULN if documented liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x upper limit of normal (ULN) if no liver involvement or =<  x the ULN if documented liver involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN; for subjects hepatic metastases, ALT and AST =<  x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN, unless clearly due to disease involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > . x ULN; for patients with liver metastases: AST/ALT >  x ULN
Liver function abnormality as defined by total bilirubin >.  ULN or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >.  ULN (except for subjects with liver involvement, who can have AST/ALT >  ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<  x ULN (=<  x ULN if patients have liver involvement with MM)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >  x ULN, unless related to ALL liver infiltration
Aspartate aminotransferase or alanine aminotransferase =< . x ULN (=< . x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =<  x the ULN unless considered due to organ leukemic involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) <  x ULN, except patients who are assigned to receive docetaxel must have liver function tests (serum transaminases, bilirubin) that are within . x the ULN
Must be met within  days of CD: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x UNL (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =<  x ULN)
Alanine transaminase (ALT) and aspartate aminotransferase (AST) < . x ULN (<  x ULN if patient has liver metastasis)
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to . x ULN for the lab or less than or equal to  x ULN if liver metastasis.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x ULN; AST/ALT =<  x ULN if liver metastasis is present (to be performed within  days prior to start of study treatment)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > . X ULN, or for subjects with liver involvement AST and/or ALT >  x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN or =<  x ULN if liver involvement
Within  days of enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > . x ULN, unless there are liver metastases in which case AST and ALT or >  x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN; =<  x ULN if due to lymphoma involvement, without use of growth factor support for  week
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN (=< . x ULN for patients with liver involvement of their cancer)
Adequate liver function (total bilirubin ?. X ULN (or ? X ULN in patients with documented Gilbert's syndrome or for patients with hyperbilirubinemia considered due to myeloid disease), alanine aminotransferase [ALT] and aspartate aminotransferase [AST] ? X ULN (or ? X ULN for patients with liver involvement of their myeloid disease)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN; NOTE: concomitant elevations in ALT/AST above . x ULN is not permitted
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< . x ULN, except if the elevations are due to hepatic metastases, in which case ALT and AST must be =<  x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN OR <  x ULN if patient has liver metastasis
Within  days prior to first dose of study drug treatment: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =<  x ULN with the following exceptions:\r\n* Patients with documented liver metastases: AST and/or ALT =<  x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <  x ULN (<  x ULN if there is evidence of hepatic involvement by malignant disease)
Alanine aminotransferase (ALT) and aspartate aminotransferease (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN, obtained within  days prior to the first study treatment (cycle , day ) with the following exception:\r\n* Patients with liver metastases may enroll with AST and ALT =<  x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x the ULN if no liver involvement, or =<  x the ULN with liver involvement
Aspartate aminotransferases (AST) and alanine aminotransferase (ALT) =< . x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =<  x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, the AST/ALT =<  times ULN is acceptable
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <  x ULN unless related to metastatic breast cancer to the liver (in which case AST/ALT <  x ULN is allowed)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >=  x ULN (with or without liver metastasis [mets])
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < . x institutional ULN; note: patients who have both bilirubin > ULN and AST/ALT > ULN are not eligible (unless they have Gilbert's syndrome and elevations of indirect bilirubin)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<  x ULN; in the setting of metastatic disease to the liver, AST/ALT may be =<  x ULN
Aspartate and alanine aminotransferase (AST & ALT) ?. x ULN or ?. x ULN if subject has liver metastasis;
Aspartate aminotransferase (AST) =<  x ULN unless evidence of the direct liver involvement by lymphoma  then =<  x ULN
Asparate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to  x ULN for the lab. (Note: If AST and/or ALT greater than ULN, serologic testing for Hepatitis B and C must be performed and results must be negative.)
SUB-PROTOCOL AIM A: Aspartate transaminase (AST); alanine aminotransferase (ALT) =< . x ULN; NOTE: if subject has tumor involvement in the liver =<  X ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) =< . x ULN or alanine aminotransferase (ALT) =< . x ULN (Note, if both AST and ALT are done, both must be =< . x ULN) OR
Aspartate aminotransferase or alanine aminotransferase =< . x ULN (=< . x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within . x ULN, or =< . x ULN for patients with documented hepatic involvement
Aspartate aminotransferase (AST) ? . x ULN; alanine aminotransferase (ALT) ? . x ULN; AST/ALT <  x ULN if liver involvement
Prior to cyclophosphamide and T cell infusions: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<  x ULN (since all patients will have liver metastasis)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x ULN; for subjects with documented metastatic disease to the liver, AST and ALT levels =<  x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULN (or =<  x ULN if liver involved with disease
Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< . x ULN (=<  x ULN for patients with liver involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer) obtained =< days prior to randomization
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN if no liver involvement or =<  x the ULN if known liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? . x ULN unless associated with hepatic metastases, then ALT and AST ?  x ULN
Obtained within  days prior to the first study treatment (cycle , day ); aspartate aminotransferase measurement (AST) and alanine aminotransferase measurement (ALT) ? . x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT ?  x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< . x ULN or AST and ALT levels =<  x ULN (for subjects with documented metastatic disease to the liver)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN or =<  x ULN if caused by liver metastasis
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =<  x ULN, or =<  x institutional ULN in subjects with liver metastasis
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= . x ULN (for patients with known liver metastasis, AST or ALT =<  x ULN is allowed) at the screening visit
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > . x ULN (AST and ALT >  x ULN for subjects with liver metastasis)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN if no liver involvement, or =<  x ULN with liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . X ULN if no liver involvement, or =<  X ULN with liver involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x ULN for patients without liver metastasis
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . X ULN; concomitant elevations in AST/ALT above . X ULN are not permitted
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN (=< . x ULN for patients with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (or =<  x ULN if liver involved with disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . ULN (obtained within  days prior to the first study treatment [course , day ]) with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =<  x ULN
Aspartate aminotransferase (AST) ?. x ULN; ALT ?. x ULN or AST/ALT < x ULN if liver involvement
Alanine aminotransferase and aspartate aminotransferase < . of the ULN (<  x of ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<  x ULN (unless liver metastases, who can have AST/ALT =<  x ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <  x ULN (patients with documented liver metastases: AST and/or ALT =<  x ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< . x ULN (=< . x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > . x ULN in pts without liver metastasis; for pts with liver metastasis: ALT or AST > . x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? . x ULN (?  x ULN for subjects with hepatic involvement with tumor)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? . x ULN, or AST and ALT ?  x ULN if liver function abnormalities are due to underlying malignancy
Aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) =<  x ULN for the institution (=<  x ULN is acceptable if liver has tumor involvement)
Serum alanine aminotransferase/serum aspartate aminotransferase (ALT/AST) < . x ULN; for patients with liver metastases, ALT/AST <  x ULN is acceptable
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<  x ULN (for subjects with liver metastases AST/ALT may be =<  x ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < . x institutional ULN unless metastatic to liver in which case AST and ALT should be <  x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN, unless due to liver involvement with lymphoma
Serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) levels must be =< . x ULN, or =<  X ULN for patients with liver involvement by lymphoma
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN, unless ALT or AST elevation is thought to be related to underlying AML, in which case ALT and AST should be =< . x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x ULN; for subjects with documented liver metastases, the AST/ALT may be =<  x ULN
Alanine aminotransferase and AST ? .  ULN; for subjects with hepatic metastases, ALT and AST ?   ULN
Alanine aminotransferase and aspartate aminotransferase =< . x ULN or =< . x ULN in case of documented hepatic metastasis
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? . x ULN (?  x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (ALT and AST =< . x ULN is acceptable if there is liver metastasis)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN or =< . ULN if hepatic involvement is present as determined by the investigator
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =<  x ULN if no liver involvement, or =<  x ULN with liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN if no liver involvement, or =<  x ULN with liver involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < . X institutional ULN (unless demonstrated Hodgkin lymphoma involvement of the liver)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= . times the ULN (>=  x ULN for patients with liver involvement)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ?  x ULN ( x ULN for those with lymphoma involvement of the liver)
Aspartate aminotransferase (AST) =< . x ULN; alanine aminotransferase (ALT) and AST =<  x ULN is acceptable if there is liver metastasis
Alanine transaminase (alanine aminotransferase [ALT]) =<  x upper normal limit (ULN) (in the expansion cohort, patients with known liver involvement may have ALT =<  x ULN); aspartate aminotransferase (AST) =<  x ULN (in the expansion cohort, patients with known liver involvement may have AST =<  x ULN)
Have significant hepatic dysfunction (aspartate aminotransferase [AST]/alanine aminotransferase [ALT] >=  x ULN or reported liver disease)
Abnormal liver functions consisting of any of the following:\r\n* Serum bilirubin >= . x ULN (except for patients with documented Gilberts disease)\r\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= . x ULN, (for patients with known liver metastasis, AST or ALT =<  x ULN is allowed)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN in the absence of known metastatic involvement of the liver or AST and ALT =< . x ULN if there is metastatic liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?. x ULN if no liver involvement or ? x ULN with liver involvement.